Eeric Truumees1, Kevin Macadaeg2, Enrique Pena3, John Arbuckle2, Jonathan Gentile2, Robert Funk2, Devender Singh3, Sheetal Vinayek2. 1. Seton Spine and Scoliosis Center, University of Texas, Orthopaedic Surgery, 1600 West 38th Street, Suite 200, Austin, TX, 78731, USA. etruumees@ascension.org. 2. Indiana Spine Group, 13225 N. Meridian St, Carmel, IN, 46032, USA. 3. Seton Spine and Scoliosis Center, University of Texas, Orthopaedic Surgery, 1600 West 38th Street, Suite 200, Austin, TX, 78731, USA.
Abstract
PURPOSE: A prospective, single-arm, open-label study to evaluate the effectiveness of intraosseous radio frequency (RF) ablation of the basivertebral nerve (BVN) for the treatment of vertebrogenic-related chronic low back pain (CLBP) in typical spine practice settings using permissive criteria for study inclusion. METHODS: Consecutive patients with CLBP of at least 6 months duration and with Modic Type 1 or 2 vertebral endplate changes between L3 and S1 were treated with RF ablation of the BVN in up to four vertebral bodies. The primary endpoint was patient-reported change in Oswestry Disability Index (ODI) from baseline to 3 months post-procedure. Secondary outcome measures included change in visual analog scale (VAS), SF-36, EQ-5D-5L, and responder rates. RESULTS: Median age was 45 years; baseline ODI was 48.5; VAS was 6.36. Seventy-five percent (75%) of the study patients reported LBP symptoms for ≥ 5 years; 25% were actively using opioids; and 61% were previously treated with injections. Mean change in ODI at 3 months posttreatment was - 30.07 +14.52 points (p < 0.0001); mean change in VAS was - 3.50 + 2.33 (p < 0.0001). Ninety-three percent (93%) of patients achieved a ≥ 10-point improvement in ODI, and 75% reported ≥ 20-point improvement. CONCLUSIONS: Minimally invasive RF ablation of the BVN demonstrated a significant improvement in pain and function in this population of real-world patients with chronic vertebrogenic-related LBP. These slides can be retrieved under Electronic Supplementary Material.
PURPOSE: A prospective, single-arm, open-label study to evaluate the effectiveness of intraosseous radio frequency (RF) ablation of the basivertebral nerve (BVN) for the treatment of vertebrogenic-related chronic low back pain (CLBP) in typical spine practice settings using permissive criteria for study inclusion. METHODS: Consecutive patients with CLBP of at least 6 months duration and with Modic Type 1 or 2 vertebral endplate changes between L3 and S1 were treated with RF ablation of the BVN in up to four vertebral bodies. The primary endpoint was patient-reported change in Oswestry Disability Index (ODI) from baseline to 3 months post-procedure. Secondary outcome measures included change in visual analog scale (VAS), SF-36, EQ-5D-5L, and responder rates. RESULTS: Median age was 45 years; baseline ODI was 48.5; VAS was 6.36. Seventy-five percent (75%) of the study patients reported LBP symptoms for ≥ 5 years; 25% were actively using opioids; and 61% were previously treated with injections. Mean change in ODI at 3 months posttreatment was - 30.07 +14.52 points (p < 0.0001); mean change in VAS was - 3.50 + 2.33 (p < 0.0001). Ninety-three percent (93%) of patients achieved a ≥ 10-point improvement in ODI, and 75% reported ≥ 20-point improvement. CONCLUSIONS: Minimally invasive RF ablation of the BVN demonstrated a significant improvement in pain and function in this population of real-world patients with chronic vertebrogenic-related LBP. These slides can be retrieved under Electronic Supplementary Material.
Authors: Joseph S Cheng; Michael J Lee; Eric Massicotte; Bryan Ashman; Marcelo Gruenberg; Leslie E Pilcher; Andrea C Skelly Journal: Spine (Phila Pa 1976) Date: 2011-10-01 Impact factor: 3.468
Authors: Kevin E Thorpe; Merrick Zwarenstein; Andrew D Oxman; Shaun Treweek; Curt D Furberg; Douglas G Altman; Sean Tunis; Eduardo Bergel; Ian Harvey; David J Magid; Kalipso Chalkidou Journal: J Clin Epidemiol Date: 2009-05 Impact factor: 6.437
Authors: Janet K Freburger; George M Holmes; Robert P Agans; Anne M Jackman; Jane D Darter; Andrea S Wallace; Liana D Castel; William D Kalsbeek; Timothy S Carey Journal: Arch Intern Med Date: 2009-02-09
Authors: M F Janssen; A Simon Pickard; Dominik Golicki; Claire Gudex; Maciej Niewada; Luciana Scalone; Paul Swinburn; Jan Busschbach Journal: Qual Life Res Date: 2012-11-25 Impact factor: 4.147
Authors: Maria Tzika; George K Paraskevas; Maria Piagkou; Apostolos K Papatolios; Konstantinos Natsis Journal: Surg Radiol Anat Date: 2021-02-17 Impact factor: 1.246
Authors: Aaron Conger; Matthew Smuck; Eeric Truumees; Jeffrey C Lotz; Michael J DePalma; Zachary L McCormick Journal: Pain Med Date: 2022-07-20 Impact factor: 3.637
Authors: Zachary L McCormick; Beau P Sperry; Barret S Boody; Joshua A Hirsch; Aaron Conger; Katrina Harper; Jeffrey C Lotz; Taylor R Burnham Journal: Pain Med Date: 2022-07-20 Impact factor: 3.637
Authors: Zachary L McCormick; Aaron Conger; Matthew Smuck; Jeffrey C Lotz; Joshua A Hirsch; Colton Hickman; Katrina Harper; Taylor R Burnham Journal: Pain Med Date: 2022-07-20 Impact factor: 3.637
Authors: Ivan Urits; Nazir Noor; Arjun Singh Johal; Joseph Leider; Joseph Brinkman; Nathan Fackler; Neeraj Vij; Daniel An; Elyse M Cornett; Alan D Kaye; Omar Viswanath Journal: Pain Ther Date: 2020-10-31
Authors: Vinicius Tieppo Francio; David Sherwood; Eric Twohey; Brandon Barndt; Robert Pagan-Rosado; James Eubanks; Dawood Sayed Journal: J Pain Res Date: 2021-06-23 Impact factor: 3.133